Figure 2.

Summary of switching reasons of previous antipsychotic treatment of all enrolled patients. For the enrolled population, there were 9 subjects who did not receive any antipsychotics at enrollment. For the remaining 471 subjects, 449 received antipsychotics within 30 days prior to enrollment. The treatments included oral risperidone for 201 subjects (44.77%), olanzapine for 41 subjects (9.13%), quetiapine for 31 subjects (6.90%), aripiprazole for 30 subjects (6.68%), and other treatments for 187 subjects (41.65%). The major reason of switching treatment was insufficient efficacy, accounting for a total of 344 subjects. AEs (92 subjects), noncompliance (51 subjects), and other (2 subjects) were the reasons for switching. Twenty-two subjects received antipsychotics > 30 days prior to enrollment. The switching reasons were insufficient efficacy (n = 10), side effects (n = 1), noncompliance (n = 11), and other (n = 1).

Huang et al. BMC Clinical Pharmacology 2012 12:1   doi:10.1186/1472-6904-12-1
Download authors' original image